Insider Selling: Natera (NASDAQ:NTRA) Director Sells $23,348.36 in Stock

Natera, Inc. (NASDAQ:NTRA) Director Rowan Chapman sold 122 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $191.38, for a total value of $23,348.36. Following the transaction, the director owned 5,752 shares in the company, valued at approximately $1,100,817.76. This trade represents a 2.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Natera Price Performance

Shares of NTRA stock opened at $202.73 on Friday. The firm has a 50-day moving average of $216.05 and a 200-day moving average of $207.05. Natera, Inc. has a one year low of $125.38 and a one year high of $256.36. The company has a market cap of $28.73 billion, a P/E ratio of -132.50 and a beta of 1.65.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.81. The business had revenue of $665.50 million for the quarter, compared to analysts’ expectations of $600.68 million. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. During the same period in the previous year, the company earned ($0.41) earnings per share. As a group, research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in NTRA. Reflection Asset Management bought a new position in shares of Natera in the fourth quarter valued at approximately $29,000. Palladiem LLC bought a new stake in Natera during the 4th quarter worth approximately $31,000. Horizon Investments LLC bought a new stake in Natera during the 3rd quarter worth approximately $32,000. Bank of Jackson Hole Trust lifted its stake in Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after purchasing an additional 83 shares in the last quarter. Finally, Sound Income Strategies LLC lifted its stake in Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after purchasing an additional 110 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analyst Ratings Changes

NTRA has been the topic of a number of recent analyst reports. Citigroup started coverage on Natera in a report on Wednesday, January 7th. They set a “buy” rating and a $300.00 price target on the stock. BTIG Research lifted their target price on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. Morgan Stanley cut their price target on shares of Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. JPMorgan Chase & Co. raised their price objective on shares of Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $253.47.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.